ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan's Eisai to launch clinical trial for coronavirus treatment

Drugmaker to use once-promising sepsis medication in 500-person test

Eisai will soon start clinical trials in the U.S. for Eritoran. (Photo by Kosaku Mimura)

TOKYO -- Japanese pharmaceutical Eisai is set to begin clinical trials in the U.S. for Eritoran, a drug initially developed as a treatment for severe sepsis but which could be useful in the fight against the new coronavirus, the company announced Wednesday.

Eritoran is being studied as a way of treating the virus while preventing lung injury.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more